New lung drug ENV-101 put through safety checks in healthy volunteers
NCT ID NCT07454291
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-stage study tests how a new drug called ENV-101 (taladegib) interacts with two standard medicines for idiopathic pulmonary fibrosis (IPF): nintedanib and pirfenidone. About 57 healthy adults will take ENV-101 alone and with these drugs to measure how the body absorbs and processes them. The goal is to gather safety and drug-level data, not to treat IPF.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBrisbane, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
taladegib (ENV-101)
What this could lead to
If successful, this study could help doctors understand how to safely combine ENV-101 with existing IPF treatments.
What could go wrong
This is an early-phase study in healthy people, not patients. It only measures drug levels and interactions, not whether ENV-101 works for IPF.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.